Clinical Trials Logo

Filter by:
NCT ID: NCT00469378 Completed - Multiple Sclerosis Clinical Trials

Study Of White Blood Cells In The Cerebrospinal Fluid And Blood Of Patients With Relapsing Forms Of Multiple Sclerosis

Start date: July 2007
Phase: Phase 2
Study type: Interventional

This is a study to count the number of white blood cells in the cerebrospinal fluid and blood at the beginning and end of treatment with firategrast and at 4 and 12 weeks after stopping firategrast. Cerebrospinal fluid flows through and protects the brain and spinal cord. It is important to understand what happens to the number of white blood cells because they are important in preventing infections.

NCT ID: NCT00468728 Completed - Diarrhea Clinical Trials

PAR-101/OPT-80 Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD)

Start date: April 2007
Phase: Phase 3
Study type: Interventional

This is a comparative study to investigate the safety and efficacy of PAR-101/OPT-80 (fidaxomicin) versus vancomycin in subjects with Clostridium difficile-associated diarrhea (CDAD).

NCT ID: NCT00468546 Completed - Clinical trials for Rheumatoid Arthritis

A Study to Evaluate the Safety and Efficacy of MabThera (Rituximab) in Combination With Methotrexate (MTX) in Participants With Active Rheumatoid Arthritis Who Failed on Anti-Tumor Necrosis Factor Alpha Therapy

Start date: July 2003
Phase: Phase 3
Study type: Interventional

This study will assess the safety and efficacy of rituximab combined with MTX in participants with active RA who have had an inadequate response to anti-TNF alpha therapy. The anticipated time in the study is up to 2 years and the target sample size is 500 participants. Eligible participants may receive re-treatment with rituximab under a separate protocol WA17531.

NCT ID: NCT00464633 Completed - Clinical trials for Leukemia, Lymphocytic, Chronic

Alvocidib in Patients With Previously Treated Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia Arising From Chronic Lymphocytic Leukemia (CLL)

Start date: March 2007
Phase: Phase 2
Study type: Interventional

Multicenter, open-label, study of alvocidib in previously treated chronic lymphocytic leukemia patients. Primary objective is to determine overall response rate. The secondary objectives are: - to assess overall safety, - to assess duration of response, progression free survival, and overall survival. Clinical benefit and pharmacokinetics parameters are also evaluated.

NCT ID: NCT00464503 Completed - Clinical trials for Statin Induced Proteinuria

Statins and the Urinary Proteome

Start date: September 2007
Phase: N/A
Study type: Interventional

This study aims to investigate whether statines (rosuva- and pravastatin) induce tubular proteinuria.

NCT ID: NCT00464165 Completed - Smoking Cessation Clinical Trials

Comparison of Efficacy and Safety of Rimonabant 5mg/Day or 20mg/Day Versus Placebo in Smoking Cessation

STRATUS-EU
Start date: November 2002
Phase: Phase 3
Study type: Interventional

The primary objective is to assess the efficacy of 2 fixed doses of rimonabant versus placebo on abstinence from tobacco use in cigarette smokers. The secondary objective is to evaluate the effects of rimonabant on craving and weight and on the clinical and biological safety and tolerability of rimonabant in a population of cigarette tobacco smokers during a 10-week treatment period and to observe the percentage of abstinent subjects during a 40-week follow-up post treatment.

NCT ID: NCT00464139 Completed - Infertility Clinical Trials

Prevalence of Endometriosis in a Well Defined Group of Infertile Women

Start date: January 2007
Phase: N/A
Study type: Observational

At the Leuven University Fertility Centre (LUFC) of the Department of Obstetrics and Gynecology of the University Hospitals Leuven, Belgium, a retrospective epidemiological prevalence study based on an electronic search of patient files was performed to determine the prevalence of histologically proven endometriosis in a subset of infertile women with a regular cycle (variation 21 - 35 days), a partner with normal sperm and no previous surgical diagnosis of endometriosis.

NCT ID: NCT00463866 Completed - Asthma Clinical Trials

Local Phase 4 Pan-European SMART Study

Start date: March 2007
Phase: Phase 4
Study type: Interventional

The purpose of this study is to evaluate the effect of two different maintenance doses of Symbicort Maintenance And Reliever Therapy (SMART) in adult asthmatic patients. A 6 month treatment period

NCT ID: NCT00463788 Completed - Breast Neoplasm Clinical Trials

Cetuximab and Cisplatin in the Treatment of "Triple Negative" (Estrogen Receptor [ER] Negative, Progesterone Receptor [PgR] Negative, and Human Epidermal Growth Factor Receptor 2 [HER2] Negative) Metastatic Breast Cancer

BALI-1
Start date: June 2007
Phase: Phase 2
Study type: Interventional

The primary objective of this study is to determine whether overall response to cetuximab combined with cisplatin is better than overall response to cisplatin alone together with showing that the overall response for cetuximab and cisplatin was above a pre-specified threshold of 0.2 in the treatment of "triple negative" metastatic breast cancer. The secondary objective of this study is to compare the differences between the two treatment groups using the following criteria : Progression-Free Survival (PFS) Time, Overall Survival (OS), Time to Response (TTR) and Safety.

NCT ID: NCT00463515 Completed - Clinical trials for Non-Small-Cell-Lung Cancer

Evaluation of Carboplatin Plus Gemcitabine Followed by Concomitant Chemoradiation for Non-resectable Stage III NSCLC

CHER@NOS
Start date: January 2003
Phase: Phase 2
Study type: Interventional

The aim of this study is to evaluate whether by combining a carboplatin-gemcitabine based induction chemotherapy with weekly cisplatin during standard thoracic radiotherapy it is possible to obtain optimal efficacy with minimal toxicity. Patients will be treated with 3 cycles of induction chemotherapy, unless there is the occurrence of early intrathoracic progression of disease. The induction chemotherapy is then to be followed by chemo-radiotherapy.